Overview

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion
Phase:
Phase 3
Details
Lead Sponsor:
Abnoba Korea
Collaborator:
Abnoba Gmbh
Treatments:
Viscum album peptide